Abstract
This is an open-label, single arm study of 52 weeks duration. The study will assess the safety and efficacy of lebrikizumab in adolescent participants (≥12 to <18 years weighing 40 kilograms with moderate-to-severe atopic dermatitis ad who are candidates for systemic therapy.>
